Guru Sonpavde: ctDNA for Evaluating Minimal Residual Disease in Bladder Cancer
Guru Sonpavde, Phase I and GU Oncology Director at Advent Health Cancer Institute, posted on LinkedIn:
“Circulating tumor (ct)-DNA for evaluating MRD (molecular/minimal residual disease) in bladder cancer: In this editorial European Urology, we discuss tumor-informed ctDNA:
1) based on whole-exome sequencing of the tumor,
2) based on whole genome sequencing (WGS) of the tumor and
3) a novel strategy using WGS of tumor and peripheral blood mononuclear cells with subsequent bioinformatics analyses for potentially more accurate ctDNA detection Lars Dyrskjøt Iver Nordentoft – pleased to coauthor from AdventHealth Central Florida cancer Institute– editorial led by Jason Brown– with coauthor Pedro C Barata, MD MSc FACP Lake Health/University Hospital Seidman Cancer Center.”
Visit the article website.
Source: Guru Sonpavde/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023